When Neuroprotection Becomes a Potential Ally of High-Grade Glioma
- 1 May 2019
- journal article
- news
- Published by Elsevier in World Neurosurgery
- Vol. 125, 529-530
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastomaCancer, 2009
- Neuroprotective potential of erythropoietin and darbepoetin alfa in an experimental model of sciatic nerve injuryJournal of Neurosurgery: Spine, 2007
- Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growthEuropean Journal of Cancer, 2007
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Brain and cancer: The protective role of erythropoietinMedicinal Research Reviews, 2004
- Erythropoietin as an antiapoptotic, tissue-protective cytokineCell Death & Differentiation, 2004
- Erythropoietin as a Tissue-Protective Cytokine in Brain Injury: What Do We Know and Where Do We Go?The Neuroscientist, 2004
- Erythropoietin stimulates proliferation of human renal carcinoma cellsKidney International, 2000
- Brain Capillary Endothelial Cells Express two forms of Erythropoietin Receptor mRNAEuropean Journal of Biochemistry, 1996